Blue Star Foods Corp. Engages ShareIntel to Combat Alleged Illegal Short Selling
01 févr. 2023 08h30 HE
|
Blue Star Foods Corp.
Blue Star Takes Action to Strengthen Measures to Safeguard Shareholder Interests Miami, FL, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or...
Blue Star Foods Enters into Supply Agreement for Up to $4 Million Annually with Just Food For Dogs
31 janv. 2023 08h30 HE
|
Blue Star Foods Corp.
Will Supply Wild Caught Cod as Ingredient for its Gourmet Dog Food Miami, FL, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ:...
Blue Star Foods Highlights Sustainability in New ESG Report
24 janv. 2023 08h30 HE
|
Blue Star Foods Corp.
Working to Improve the Lives of Artisan Fishers and the Sustainability of the Fishery Miami, FL, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or...
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
19 déc. 2022 07h00 HE
|
Revolution Medicines, Inc.
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric...
Blue Star Foods’ Taste of BC Aquafarms Submits Application for New and Expanded Land-Based Salmon Aquaculture Farm
12 déc. 2022 08h30 HE
|
Blue Star Foods Corp.
Will Utilize Proven Technology and Process for up to 1500 Metric Tons Capacity Miami, FL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or...
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
07 déc. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Blue Star Foods Reports Growth of 28% to $10.7 Million Revenue for the Nine Months Ended September 30, 2022
15 nov. 2022 08h30 HE
|
Blue Star Foods Corp.
Highlighted by Initial $1.0 Million Revenue from Soft-Shell Crab RAS Miami, FL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ:...
Revolution Medicines to Participate in Upcoming Investor Conferences
09 nov. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
07 nov. 2022 16h05 HE
|
Revolution Medicines, Inc.
Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...